Lack of effect of prolonged treatment with liraglutide on cardiac remodeling in rats after acute myocardial infarction
K Kyhl, J Lønborg, B Hartmann, H Kissow, SS Poulsen… - Peptides, 2017 - Elsevier
Following the acute phase of a myocardial infarction, a set of structural and functional
changes evolves in the myocardium, collectively referred to as cardiac remodeling. This …
changes evolves in the myocardium, collectively referred to as cardiac remodeling. This …
[PDF][PDF] Liraglutide improves myocardial fibrosis after myocardial infarction through inhibition of CTGF by activating cAMP in mice.
DD Huang, HF Huang, Q Yang… - European Review for …, 2018 - europeanreview.org
OBJECTIVE: To study the role and mechanism of liraglutide in myocardial fibrosis after
myocardial infarction (MI). MATERIALS AND METHODS: A total of 72 C57/BL male mice …
myocardial infarction (MI). MATERIALS AND METHODS: A total of 72 C57/BL male mice …
Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis
T Gaspari, M Brdar, HW Lee, I Spizzo… - Diabetes and …, 2016 - journals.sagepub.com
Background: Glucagon-like peptide-1 receptor agonists may have a role in modulation of
cardiac fibrosis. Our study aimed to determine the effect of the glucagon-like peptide-1 …
cardiac fibrosis. Our study aimed to determine the effect of the glucagon-like peptide-1 …
[HTML][HTML] Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute …
T Nozue, M Yamada, T Tsunoda, H Katoh, S Ito… - Heart and vessels, 2016 - Springer
The clinical efficacy of glucagon-like peptide-1 (GLP-1) analogs in patients with acute
myocardial infarction (AMI) is uncertain. The purpose of the present study was to evaluate …
myocardial infarction (AMI) is uncertain. The purpose of the present study was to evaluate …
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
MH Noyan-Ashraf, MA Momen, K Ban, AM Sadi… - Diabetes, 2009 - Am Diabetes Assoc
OBJECTIVE Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2
diabetes, and transient GLP-1 administration improved cardiac function in humans after …
diabetes, and transient GLP-1 administration improved cardiac function in humans after …
[HTML][HTML] The Glp-1 analog liraglutide protects against angiotensin II and pressure overload-induced cardiac hypertrophy via PI3K/Akt1 and AMPKa signaling
R Li, Y Shan, L Gao, X Wang, X Wang… - Frontiers in …, 2019 - frontiersin.org
The Glp-1 analog, liraglutide (Lir), has been shown to reduce infarct size and improve
cardiac function after myocardial ischemia in rodents with or without diabetes. However, the …
cardiac function after myocardial ischemia in rodents with or without diabetes. However, the …
[HTML][HTML] Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection
GLP-1R agonists improve outcomes in ischemic heart disease. Here we studied GLP-1R-
dependent adaptive and cardioprotective responses to ventricular injury. Glp1r−/− hearts …
dependent adaptive and cardioprotective responses to ventricular injury. Glp1r−/− hearts …
Modulation of myocardial injury and collagen deposition following ischaemia–reperfusion by linagliptin and liraglutide, and both together
X Wang, Z Ding, F Yang, Y Dai, P Chen… - Clinical …, 2016 - portlandpress.com
Studies have indicated that dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like
peptide-1 (GLP-1) agonists reduce infarct size after myocardial ischaemia. Whether these …
peptide-1 (GLP-1) agonists reduce infarct size after myocardial ischaemia. Whether these …
[HTML][HTML] Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model
J Kristensen, UM Mortensen, M Schmidt… - BMC cardiovascular …, 2009 - Springer
Background Glucagon-like peptide 1 (GLP1) analogues are promising new treatment
options for patients with type 2 diabetes, but may have both potentially beneficial and …
options for patients with type 2 diabetes, but may have both potentially beneficial and …
[HTML][HTML] Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin …
LH Zhang, XF Pang, F Bai, NP Wang, AI Shah… - … drugs and therapy, 2015 - Springer
Purpose The glucagon-like peptide-1 (GLP-1) has been shown to exert cardioprotective
effects in animals and patients. This study tests the hypothesis that preservation of GLP-1 by …
effects in animals and patients. This study tests the hypothesis that preservation of GLP-1 by …